1231952-55-8 Usage
General Description
SRT3025, also known as N-((1-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl) ethyl)-2-methyl-2-phenylpropanamide, is a synthetic chemical compound that has been studied for its potential therapeutic effects in various medical conditions. It is a selective modulator of the SIRT1 protein, a key regulator of cellular metabolism and longevity. Research has shown that SRT3025 has the potential to improve mitochondrial function, increase insulin sensitivity, and reduce inflammation, making it a promising candidate for the treatment of metabolic disorders such as diabetes and obesity. Additionally, SRT3025 has also been investigated for its potential anti-aging and neuroprotective properties, with some evidence suggesting that it may have beneficial effects on cognitive function and neurological health. However, further research is needed to fully understand the safety and efficacy of SRT3025 for these applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1231952-55-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,1,9,5 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1231952-55:
(9*1)+(8*2)+(7*3)+(6*1)+(5*9)+(4*5)+(3*2)+(2*5)+(1*5)=138
138 % 10 = 8
So 1231952-55-8 is a valid CAS Registry Number.
1231952-55-8Relevant articles and documents
THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS
-
Page/Page column 88; 89, (2010/08/05)
Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
